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Uncoupling of EGFR–RAS signaling and nuclear localization
of YBX1 in colorectal cancer
F Roßner1,2, C Gieseler1, M Morkel1, H-D Royer3, M Rivera4, H Bläker1,2, M Dietel1, R Schäfer1,2 and C Sers1,2
The transcription factor YBX1 can act as a mediator of signals transmitted via the EGFR–RAS–MAPK axis. YBX1 expression has been
associated with tumor progression and prognosis in multiple types of cancer. Immunohistochemical studies have revealed
dependency between YBX1 expression and individual EGFR family members. We analyzed YBX1 and EGFR family proteins in a
colorectal cancer (CRC) cohort and provide functional analyses of YBX1 in the context of EGFR–RAS–MAPK signaling.
Immunohistochemistry for YBX1 and EGFR family receptors with two antibodies for YBX1 and EGFR were performed and related to
clinicopathological data. We employed Caco2 cells expressing an inducible KRASV12 gene to determine effects on localization and
levels of YBX1. Mouse xenografts of Caco2-KRASV12 cells were used to determine YBX1 dynamics in a tissue context. The two
different antibodies against YBX1 showed discordant immunohistochemical stainings in cell culture and clinical specimens.
Expression of YBX1 and EGFR family members were not correlated in CRC. Analysis of Caco2 xenografts displayed again
heterogeneity of YBX1 staining with both antibodies. Our results suggest that YBX1 is controlled via complex regulatory
mechanisms involving tumor stroma interaction and signal transduction processes. Our study highlights that YBX1 antibodies have
different speciﬁcities, advocating their use in a combined manner.
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INTRODUCTION
Y-Box-binding protein 1 (YBX1) is the most prominent
member of the Y-Box-binding protein family, comprising of
transcription factors binding to DNA sequences called
Y-Boxes.1–3 YBX1 has been associated with multiple cancer-
related processes such as DNA-repair, extracellular stress
response,4–7 transcriptional4,8–10 and translational control8,10–12
as well as cell proliferation.3,13 YBX1 was suggested to be a
prognostic clinical biomarker in different cancer types and
correlated with poor prognosis in breast cancer,14,15 lung
cancer,16,17 multiple myeloma,18 osteosarcoma,19 synovial
sarcoma,20 prostate cancer21 and in ovarian cancer.22 Recently,
Woolley et al.,23 challenged the relevance of various prognostic
data due to the fact that different YBX1 antibodies recognize
speciﬁc but distinct epitopes and thereby provide incompatible
information on YBX1 expression, nuclear or cytoplasmic
localization.
YBX1 has also been singled out as an experimental therapeutic
target. SiRNA-dependent knockdown unraveled a functional role
of YBX1 in tumor invasion, proliferation and apoptosis.18,24,25 YBX1
is involved in chemotherapy response.18,19,26 Intracellular localiza-
tion is essential for YBX1 function and a complex regulation
underlies the translocation of YBX1 between cytoplasm and
nucleus. Bargou et al.27 reported that nuclear localization of YBX1
is associated with drug resistance in human breast cancer. In
lung cancer, nuclear localization of YBX1 is correlated with EGFR
and LRP (lung resistance protein) expression.28 In colorectal
cancer (CRC), YBX1 has been identiﬁed as a prominent
mediator of malignant properties downstream of the
EGFR–RAS–MAPK signaling cascade.29 NFY/YBX1-binding sites
were overrepresented among RAS/MAPK target genes, YBX1
binding was enhanced on a group of RAS/MAPK target genes in
KRAS-transformed CRC cells and nuclear YBX1 staining was
detected in lung metastasis of CRC. A subgroup of genes targeted
via YBX1 in CRC had been identiﬁed earlier as YBX1 target genes in
breast cancer.30
Several levels of interaction exist between YBX1 and receptor
tyrosine kinases of the EGFR family, consisting of EGFR
(also known as ERBB1 and HER1) ERBB2 (also known as HER2),
ERBB3 (HER3) and ERBB4 (HER4). In breast carcinoma cells,
but not in CRC cells, YBX1 was found to bind to the promoter
and act as a transcriptional activator of the EGFR gene.31 YBX1
mediated resistance to anti-ERBB2 therapy via a complex,
RSK-dependent mechanism32 and prevents apoptosis in
ERBB2-overexpressing breast cancer cells.33 In contrast to the
well-known link between YBX1 and EGFR in breast or lung
cancer, there is little knowledge about the interaction of YBX1
and the EGFR family in CRC.
The aim of this study is to examine a potential prognostic
correlation between YBX1 and/or EGFR family expression in a
large colon carcinoma cohort. We applied two antibodies against
different epitopes of the YBX1 protein (YBX1n27 and YBX1c3)
and examined the staining patterns. We also investigated
YBX1 expression and its dependency on RAS signaling in
KRAS-inducible transgenic colon cancer cell lines and mice, to
provide a rationale for the observed sub-cellular localization of
YBX1 in CRC tissue.
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RESULTS
Expression of YBX1 and EGFR family members is independent in
CRC
We performed immunohistochemical staining for YBX1 in a cohort
of 423 CRC samples using 2 different YBX1 antibodies directed
against the C-terminal (YBX1c) and the N-terminal domain
(YBX1n).
Assessing YBX1c antibody, we found weak cytoplasmic staining
in 169 cases (39.9%), moderate staining in 76 cases (18.0%) and
strong staining in 82 cases (19.4%). Ninety-six cases were negative
(22.7%). We observed focal nuclear staining in six cases
(1.4%; Figure 1a upper panel). With YBX1n antibody, we observed
weak cytoplasmic staining in 234 cases (55.3%), moderate
cytoplasmic staining in 42 cases (9.9%) and strong cytoplasmic
staining in 17 cases (4.0%). One hundred thirty cases (30.8%) were
negative. Focal nuclear staining by YBX1n was observed in four
cases (1.0%; Figure 1a lower panel). These data indicate that
antigen detection is stronger using the YBX1c antibody. In full
section tumor tissue slides, we found a homogeneous staining
result throughout the tumor. We did not detect differences in
staining at the invasion front (Supplementary Figure S8). In total,
the 2 YBX1 antibodies, despite being directed against the same
protein, displayed discordant staining in 250 cases (Figure 1b).
Sixty-one cases showed a low-expression pattern and 32 cases
showed a high-expression pattern detectable with YBX1c, whereas
YBX1n did not detect the antigen in these cases. Fifty-two
specimens showed a low-expression pattern and seven showed a
high-expression pattern by staining with YBX1n, whereas YBX1c
was negative in these cases. Nuclear YBX1 protein was equally
detected by YBX1c and YBX1n in three specimens (30%). In one
case, YBX1n staining showed a focal nuclear pattern, whereas
YBX1c staining did not detect nuclear YBX1.
The EGFR receptor revealed a diffusely distributed cytoplasmic
granular pattern (Figure 2a). Two hundred thirty six cases (55.8%)
were weakly positive, 61 cases (14.4%) stained moderately and a
strong cytoplasmic staining was observed in 19 cases (4.5%), while
107 cases (25.3%) were negative. The ERBB2 receptor displayed a
regular distributed cytoplasmic staining, with 258 cases (61.0%)
showing weak cytoplasmic staining, 63 cases (14.9%) stained
moderately and 15 cases (3.5%) showed a strong cytoplasmic
staining (Figure 2a). No staining was observed in 87 cases (20.6%).
C-terminal ERBB4 antibody showed a weak cytoplasmic signal in
219 cases (51.8%), moderate staining in 53 cases (12.5%) and
strong staining in 3 cases (0.7%; Figure 2b). No staining was
observed in 148 cases (35.0%). The N-terminal ERBB4 antibody
showed weak cytoplasmic staining in 144 cases (34.0%), moderate
cytoplasmic staining in 34 cases (8.0%) and strong cytoplasmic
staining in 18 cases (4.3%). No staining was observed in 227 cases
(53.7%; Figure 2b). The 2 ERBB4 antibodies displayed discordant
staining in 266 cases (Supplementary Figure S2). One hundred
fourteen specimens showed a low-expression pattern and 28
cases showed a high-expression pattern detectable by ERBB4c
staining, whereas the ERBB4n antibody showed no staining in
these cases. ERBB4n staining showed low antigen expression
patterns in 56 cases and high-expression patterns in 7 specimens,
whereas ERBB4c showed no staining in these cases. As expected,
nuclei were never stained with any antibody directed against
EGFR family members. Data for ERBB3 in CRC will be presented
elsewhere (manuscript in preparation). Full section tumor tissue
slides showed only faint and inconspicuous intra-tumor staining
differences. ERBB4 antibodies showed more differences in 10%
(ERBB4n) and 30% (ERBB4c) of the tumor tissue (Supplementary
Figures S3 and S4).
We correlated the staining patterns for YBX1 and the EGFR
family members using a χ2-test. Importantly, we could not detect a
signiﬁcant correlation between YBX1 expression and patterns
obtained for any of the ERBB proteins, also irrespective of the
intracellular localization of YBX1 (Table 1). Comprehensive
assessment of discrepancy levels between the antibodies
conﬁrmed previous ﬁndings (Supplementary Figure S5). The vast
majority of tumors showed only 1–5 of 12 score points expression
difference between the antibodies. YBX1n and EGFR displayed
the highest number of cases with concordant staining
(n= 115/27, 2%), YBX1c and EGFR had the fewest number of
cases with concordant staining (n= 49/11, 6%).
Statistical analyses of clinical parameters and survival analysis
χ2-tests indicate that YBX1n positivity, but not YBX1c positivity,
obtained in primary CRC reached a borderline signiﬁcant negative
correlation with the propensity to metastasize (Pearson—χ2: 4.09;
P= 0.043), that is, a lower number of metastasized tumors were
scored YBX1n positive than expected (residual value: − 6.4;
Table 2A). Patients with YBX1n-positive tumors (independent of
the localization) exhibited increased survival compared with
patients with YBX1n-negative tumors (P= 0.016; Supplementary
Figure S6C). A tendency (P= 0.45) is also visible on splitting tumors
into low- and high-YBX1 expression subgroups (Supplementary
Figure S6D). YBX1c staining did not show signiﬁcant association
with clinical parameters and Kaplan–Meier survival analysis
showed no advantage in survival for YBX1c-negative tumors
(P= 0.977), nor was there a signiﬁcant difference between
high- and low-expression subgroups (P= 0.922; Supplementary
Figure S6A and B).
ERBB2 expression is statistically signiﬁcantly correlated with
tumor localization (P= 0.005), with a higher number of
ERBB2-positive cases in the left colon. Further correlations
between EGFR family members (ERBB1; ERBB2; ERBB4) with
clinicopathologic data were not signiﬁcant (Tables 2B and C).
Multilinear regression analysis showed that expression patterns
obtained with antibodies against YBX1c, YBX1n and the EGFR
family proteins are not correlated with clinicopathologic data
(Supplementary table S1).
EGFR/RAS signaling can modulate YBX1 localization in vivo in CRC
cells and intestinal tissues
The immunohistochemical investigation revealed a low number of
specimens with nuclear YBX1, although we have found nuclear
YBX1 in a limited set of pulmonary metastases of CRC before.27 We
therefore investigated functional mechanisms contributing to
differential YBX1 localization.
We used Caco2 CRC cells harboring an inducible KRASV12
oncogene/green ﬂuorescent protein (GFP) transgene and tested
YBX1 expression via immunoﬂuorescence. In non-induced cells,
we observed strictly distinct staining patterns using YBX1c and
YBX1n antibodies. The YBX1c antibody displayed a cytoplasmic
perinuclear staining, while the YBX1n antibody stained the
protein in the nucleus (Figure 3a). Following RAS induction, the
YBX1n-positive signals ﬁrst accumulated in a few nuclei
(Figure 3b) and after 96 h a strong and condensed nuclear YBX1n
signal was detected, whereas the YBX1c signal remained peri-
nuclear. Both, YBX1c and YBX1n staining intensity increased after
KRASV12 induction in a subset of cells. Other cells in direct
neighborhood did not show increased staining despite efﬁcient
RAS activation (as judged by GFP ﬂuorescence linked to KRAS).
We also tested the localization of YBX1 in the intestine of
transgenic mice harboring an inducible KRASV12 transgene. In the
non-induced intestine, both antibodies showed robust YBX1
protein expression, which was cytoplasmic in the villus but
cytoplasmic and nuclear in the crypt compartment. In contrast,
4 days following induction of the KRASV12 transgene both
antibodies displayed combined cytoplasmic and nuclear signals
throughout the crypt–villus axis (Supplementary Figure S7). To test
a potential increase in YBX1 total protein levels following RAS or
EGFR activation, we performed western blot analysis of Caco2 cells
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Figure 1. (a) Immunohistochemical staining of YBX1c (upper part) and YBX1n (lower part) with low (+) and high (+++) expression proﬁles.
Magniﬁcation: × 200. Insets: nuclear staining, × 400 magniﬁcation. (b) Immunohistochemical staining of YBX1c and YBX1n showing the same
tumor sample with marked differences in staining. Scale bar: 100 μm.
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Figure 2. (a) Immunohistochemical staining of HER1/ERBB1, HER2/ERBB2 and with low (+) and high (+++) expression.
(b) Immunohistochemical staining of c-terminal and n-terminal HER4/ERBB4 with low (+) and high (+++) expression. Magniﬁcation:
× 200. Scale bar: 100 μm.
Y-box-binding protein 1 in colorectal cancer
F Roßner et al
4
Oncogenesis (2016), 1 – 13
after KRASV12 induction and after addition of the EGFR ligand
TGFα. We also tested the impact of MEK inhibition. Transgenic RAS
expression became visible 24 h following doxycycline-induction
and was most prominent after 48 h (Figure 4). Concomitant
activation of MAPK signaling was evident via increased pERK
levels, however, there was no change in YBX1c-positive or EGFR-
positive cells. Likewise, treatment of the cells with TGFα-induced
pERK levels (Figure 4a, 30 min; 4 h), however, there was no effect
on YBX1c staining. Similar results were obtained using the YBX1n
antibody, albeit with weaker intensity due to a lower sensitivity of
the antibody on western blots (Figure 4b). These results indicate
that nuclear localization of YBX1 is detectable prior to, but
accentuated, following KRAS activation and are consistent with a
preferential detection of nuclear YBX1 using the YBX1n antibody.
The total level of YBX1 protein, however, is not increased following
activation of the EGFR–RAS–MAPK axis.
The rather uniform localization of YBX1 in the nucleus of KRAS-
induced Caco2 cells in vitro using the YBX1n antibody was in
contrast to our previous ﬁnding of low numbers of CRC
specimens, in which nuclear YBX1 was detectable. We therefore
asked whether the tumor microenvironment could modulate
YBX1 expression. We determined YBX1 expression and localization
in xenografts from KRASV12-inducible Caco2 in the absence and
presence of doxycycline, yielding KRASV12-negative and -positive
tumors. We found no signiﬁcant difference in YBX1 and EGFR
mRNA levels between KRASV12-negative and KRASV12-induced
mouse xenograft samples (data not shown). At the protein level,
we detected a moderate YBX1 staining in non-induced xenograft
tumors. The YBX1c staining pattern was largely cytoplasmic in
non-induced xenografts. Most interestingly, there was a clear
nuclear staining detectable using the YBX1n antibody (such as
tumor C3, Figure 5). Staining was stronger in xenografts derived
after KRASV12 induction as revealed with the two antibodies
(Figure 5). YBX1c staining remained mainly cytoplasmic, however,
occasional focal nuclear staining was visible (Figure 5, upper
panel, inserts C2 and C3). YBX1n showed a more variable staining
pattern within and between the individual mouse samples. The
heterogeneity of YBX1 protein expression and spatial distribution
observed with both antibodies was signiﬁcantly higher in Caco2
xenografts as compared with the cell cultures. This indicates that
in vivo, both YBX1 protein levels and intracellular localization are
most likely controlled via additional stromal effects, beyond
activation of KRAS.
Table 1. Spearman's rank correlation showing YBX1 against HER
receptor expression
HER1 HER2 HER4c HER4n
YBX1c 0.056 0.038 −0.007 0.085
Sig. (two-sided) 0.254 0.432 0.892 0.080
N 423 423 422 423
YBX1n 0.069 − 0.016 0.003 −0.044
Sig. (two-sided) 0.154 0.743 0.950 0.372
N 423 423 422 423
Table 2A. Cross-tables of expression of YBX1c and YBX1n
Parameter Total (%) YBX1c positive (%) YBX1c negative (%) P-value YBX1n positive (%) YBX1n negative (%) P-value
All cases 423 (100) 327 (77) 96 (23) 293 (69) 130 (31)
Age
472 238 (56) 192 (81) 46 (19) 0.061 172 (72) 66 (28) 0.129
o72 185 (44) 135 (73) 50 (27) 121 (65) 64 (35)
Gender
Male 235 (56) 186 (79) 49 (21) 0.311 158 (67) 77 (33) 0.311
Female 188 (44) 141 (75) 47 (25) 135 (72) 53 (28)
pT status
pT1/pT2 98 (23) 77 (79) 21 (21) 0.697 71 (72) 27 (28) 0.48
pT3/pT4 313 (74) 240 (77) 73 (23) 215 (69) 98 (31)
Nodal status
N0 214 (51) 167 (78) 47 (22) 0.716 149 (70) 65 (30) 0.871
N1 209 (49) 160 (77) 49 (23) 144 (69) 65 (31)
Metastasis
M0 369 (87) 289 (78) 80 (22) 0.193 262 (71) 107 (29) 0.043
M1 54 (13) 38 (70) 16 (30) 31 (57) 23 (43)
Grade
G1 4 (1) 2 (50) 2 (50) 0.177 1 (25) 3 (75) 0.054
G2/G3 412 (98) 322 (78) 90 (22) 287 (70) 125 (30)
R status
R0 377 (89) 290 (77) 87 (23) 0.126 263 (70) 114 (30) 0.876
R1 22 (5) 20 (90) 2 (10) 15 (68) 7 (32)
Localization
Right colon 175 (41) 136 (78) 39 (22) 0.845 118 (67) 57 (33) 0.235
Left colon 225 (53) 173 (77) 52 (23) 164 (73) 61 (27)
KRAS status
WT 327 (77) 255 (78) 72 (22) 0.836 227 (69) 100 (31) 0.954
MUT 53 (13) 42 (79) 11 (21) 37 (70) 16 (30)
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DISCUSSION
With this study we aimed to scrutinize the role of YBX1 as a
prognostic marker in a large cohort of CRCs, and to determine any
functional connection between EGFR, RAS–MAPK signaling and
YBX1 expression. We observed striking differences between YBX1
patterns detected either with YBX1n and YBX1c antibody
(Figure 1b). It was found previously that YBX1 staining can
depend on the choice of antibody. Woolley et al.23 assigned these
variations to different afﬁnities to the target and affected by
phosphorylation-induced conformational changes of the
protein.34–37 Yet, this theory was disproved by testing phosphory-
lated YBX1 in complexes immunoprecipitated with either
antibodies.23
We saw that differences in antigen staining patterns between
YBX1c and YBX1n antibodies extended beyond clinical specimens,
as they were also obvious in immunoﬂuorescence analyses of
Caco2 cells. The molecular events controlling YBX1 shuttling and
sub-cellular localization have been delineated only incompletely
until now. Raffetseder et al.38 described that YBX1 nuclear
localization is actively mediated via the splicing factor SRp30c/
SRSF9. Furthermore, Stein et al.39 described a heat-shock-induced,
rapid nuclear accumulation of YBX1-inducing MDR1 transcription,
which declined again within 4 h following heat shock. Both
examples indicate that cytoplasmic-nuclear shuttling of YBX1 is a
dynamic process. Woolley et al.23 demonstrated by immunopre-
cipitation and gel electrophoresis that the antibodies against YBX1
recognize the phosphorylated protein presumably in different
complexes. The authors concluded that one of the YBX1 epitopes
is likely to be masked within one of the complexes in the nucleus
under conditions of immunohistochemical staining. Our analysis
revealed several cases in which the YBX1c and YBX1n reacted
discordantly on the same tumor under identical processing
conditions (Figure 1b). This observation could indicate a tissue
processing effect affecting the two epitopes in a different way and
rendering either the nuclear or the cytoplasmic YBX1 inaccessible.
Thus, a negative YBX1 staining with only one of the two
antibodies does not indicate that YBX1 is not expressed or
present at very low level, but rather suggests an intracellular
molecular complex formation, which cannot be disregarded as an
artifact of tissue processing. Elucidation of the functional
relevance of these complexes will require detailed biochemical
analysis.
In our human tumor cohort, we observed low numbers with
focal nuclear staining of YBX1c and YBX1n. Regardless of the
different results obtained with the antibodies employed, we
conclude that nuclear localization of YBX1 is rare in primary CRC.
Other reports also describe low percentages of nuclear YBX1 using
immunohistochemistry in breast cancer cohorts23,40 The overall
(cytoplasmic plus nuclear) presence of YBX1 seemed sufﬁcient for
establishing prognostic relevance in several tumor entities.41–43 A
separate assessment of nuclear and cytoplasmic staining might
not be necessary. With our analysis, we were not able to deﬁne a
signiﬁcant prognostic impact for YBX1 staining in primary colon
cancer. The current results qualify our previous study, suggesting a
trend (P= 0.076) towards reduced survival of patients with strong
YBX1 cytoplasmic staining in an independent set of 118 CRC
Table 2B. Cross-tables of expression of HER1/ERBB1 and HER2/ERBB2
Parameter HER1 positive (%) HER1 negative (%) P-value HER2 positive (%) HER2 negative (%) P-value
All cases 306 (72) 107 (25) 336 (79) 87 (21)
Age
472 175 (74) 63 (26) 0.528 184 (77) 54 (23) 0.221
o72 141 (76) 44 (24) 152 (82) 33 (18)
Gender
Male 182 (77) 53 (23) 0.147 191 (81) 44 (19) 0.294
Female 134 (71) 54 (29) 145 (77) 43 (23)
pT status
pT1/pT2 72 (73) 26 (27) 0.7 75 (77) 23 (23) 0.394
pT3/pT4 236 (75) 77 (25) 252 (81) 61 (19)
Nodal status
N0 164 (77) 50 (23) 0.355 170 (79) 44 (21) 0.997
N1 152 (73) 57 (27) 166 (79) 43 (21)
Metastasis
M0 278 (75) 91 (25) 0.433 294 (80) 75 (20) 0.747
M1 38 (70) 16 (30) 42 (78) 12 (22)
Grade
G1 3 (75) 1 (25) 0.974 4 (100) 0 (0) 0.305
G2/G3 306 (74) 106 (26) 326 (79) 86 (21)
R status
R0 280 (74) 97 (26) 0.429 301 (80) 76 (20) 0.771
R1 18 (82) 4 (18) 17 (77) 5 (23)
Localization
Right colon 126 (72) 49 (28) 0.123 127 (73) 48 (27) 0.005
Left colon 177 (79) 48 (21) 189 (84) 36 (16)
KRAS status
WT 241 (74) 86 (26) 0.079 261 (80) 66 (20) 0.924
MUT 45 (85) 6 (15) 42 (79) 11 (21)
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samples and a signiﬁcant correlation between high nuclear
staining and reduced survival in pulmonary metastases
(P= 0.005).29 We suggest that correlations between nuclear YBX1
and patient outcome currently cannot be established in primary
CRC possibly owing to the fact that YBX1 translocation to the
nucleus is transient and considerably rare in non-metastatic
colonic tissue specimens. Therefore, cytoplasmic YBX1 staining
likewise does not represent a robust prognostic marker. Our
results on tissue micro arrays (TMAs) are strengthened further,
since staining of full section tumor tissues did not reveal
signiﬁcant expression heterogeneity, whether it is intratumoral
or at the invasion front, for both YBX1 antibodies (Supplementary
Figures S3 and S8).
Immunohistochemical analysis of EGFR, ERBB2 and ERBB4
receptors revealed distinct patterns for the different receptors
(Figure 2). Full section tumor tissue showed only faint and deﬁned
intra-tumor discrepancies for ERBB4 in low percentages of tumor
tissue, but eventually these are more likely ﬁxation artefacts than
true expression differences (Supplementary Figure S4). In contrast
to ﬁndings in NSCLC and breast cancer, we could not deﬁne a
statistically signiﬁcant correlation between expression of YBX1 and
EGFR family receptors in our large CRC cohort.28,44,45 Speciﬁcally,
neither a correlation between YBX1c/n with EGFR staining nor an
impact onto EGFR in Caco2 cells was visible. While this indicates
that YBX1 and EGFR are uncoupled in CRC, further functional
testing is required to exclude this relationship, for example, at the
level of receptor phosphorylation. While Fujii et al.46 described
ERBB2 dependency on nuclear YBX1 in breast cancer, another
study stated that ERBB2 is not dependent on YBX1 expression in
breast cancer.41 Similar to the latter study, no correlation could be
determined between YBX1 and ERBB2 in CRC in our cohort.
With some borderline signiﬁcant exceptions, we did not ﬁnd
compelling links between YBX1 and the EGFR family with
clinicopathological parameters in CRC.
Further investigations of the mechanisms of YBX1 expression
and localization in vitro and in vivo revealed that oncogenic KRAS
induction can lead to a condensed expression of YBX1 in Caco2
cells in vitro and to an increased nuclear shuttling in intestinal
epithelial cells in the mouse in vivo. These results provided
compelling evidence that YBX1 activity is inﬂuenced and
functionally tied to a strongly activated RAS/MEK/ERK signaling
pathway in certain experimental settings. We found highly
variable patterns of YBX1 protein localization in mouse
xenografts derived from the same KRAS-inducible Caco2 cells
used for in vitro experiments, whereas gene expression levels of
YBX1 and EGFR seemed not to be dependent on RAS signaling.
These important results suggest that YBX1 expression and
localization is controlled by a complex and as yet under-
appreciated regulatory network, and may strongly depend on
the microenvironment of tumor cells. It is important to notice
that prognostic statements and conclusions regarding YBX1
cannot be easily made without appreciation of contextual
molecular data, the histological setting and the antibodies
applied as diagnostic tools.
MATERIALS AND METHODS
Patient cohort
Our study was carried out on 423 cases of CRC parafﬁn-embedded tissue
specimens (years 1995–2012). All patients provided informed consent at
the Charité University Hospital for non-commercial and fully anonymous
tissue use for research purposes. Two hundred and thirty ﬁve patients
(55.6%) were male, 188 (44.4%) were female. Tumors were derived from
different parts of the colon. Three hundred and three cases had a Grade 2
status (71.6%). 249 cases (58.9%) inﬁltrated the subserosa (pT3 stadium). In
40 cases (9.5%), the tumor was metastasized. KRAS mutation status was
available for 380 samples. About 53 tumors were KRAS mutated (13.9%).
BRAF mutation status was available for 58 samples and 5 tumors were
BRAF mutated (8.6%) (Table 3).
Immunohistochemistry
We manufactured TMAs from the study cohort tissue. To evaluate
intra-tumor expression discrepancies and to thoroughly exclude a
sampling bias, we also evaluated representative full section tumor tissues
with high (score: 12) expression proﬁle. TMAs were manufactured as
described.47 Three representative regions with vital tumor tissue within the
donor block were chosen. TMAs, Caco2 cell line xenografts and mouse
intestine sections were cut into 2-μm slices and placed on glass slides.
Excessive parafﬁn was melted off in a microwave at 70 °C. Tissue slides
were incubated three times in 100% Xylol and descending ethanol series
of 100, 96, 90 and 80% and twice in 70% ethanol each followed by aqua
bidest washing. Antibody-dependent citrate- (1,97 mM, pH 6,0; Merck
Millipore, Merck KGaA, Darmstadt, Germany) or EDTA-buffered (1,71 mM,
pH 7,8; Sigma-Aldrich Corporation, St Louis, MO, USA) antigen-retrieval
and cooling was performed according to the manufacturer’s product guide
followed by two aqua bidest/TBS-washing steps. Blocking solution was
coated on HybriSlips (Sigma-Aldrich Corporation) and the slides were
incubated. Blocking solution was removed with aqua bidest and
TBS-washing solution and the primary antibody was applied overnight at
4 °C. The YBX1 antibodies were previously described.3,27 The appropriate
dilutions for YBX1 antibodies27 against the C-terminal epitope (YBX1c) and
the N-terminal epitope (YBX1n) were tested in distinct experiments on
tumor tissue and normal mucosa. EGFR (rabbit monoclonal EGF Receptor











All cases 276 (65) 147 (35) 196 (46) 227 (54)
Age
472 154 (65) 84 (35) 0.79 102 (43) 136 (57) 0.104
o72 122 (66) 63 (34) 94 (51) 91 (49)
Gender
Male 149 (63) 86 (37) 0.373 114 (49) 121 (51) 0.316




62 (63) 36 (37) 0.686 42 (43) 56 (57) 0.511
pT3/
pT4
205 (66) 108 (34) 146 (47) 167 (53)
Nodal status
N0 140 (65) 74 (35) 0.94 92 (43) 122 (57) 0.163
N1 136 (65) 73 (35) 104 (50) 105 (50)
Metastasis
M0 242 (66) 127 (34) 0.706 165 (45) 204 (55) 0.081
M1 34 (63) 20 (37) 31 (57) 23 (43)
Grade
G1 3 (75) 1 (25) 0.678 1 (25) 3 (75) 0.383
G2/G3 268 (65) 144 (35) 193 (47) 219 (53)
R status
R0 245 (65) 132 (35) 0.458 174 (46) 203 (54) 0.443




117 (67) 58 (33) 0.615 85 (49) 90 (51) 0.277
Left
colon
145 (64) 80 (36) 97 (43) 128 (57)
KRAS status
WT 212 (65) 115 (35) 0.479 154 (47) 173 (53) 0.449
MUT 37 (70) 16 (30) 22 (42) 31 (58)
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Figure 3. Immunoﬂuorescence of cultured Caco2 cells showing staining of YBX1n and YBX1c after 24 h (a), 48 h (b), 72 h (c) and 96 h
(d) of doxycycline (2 μg/ml) treatment. DAPI: nuclear stain, GFP: RAS expression, YB-1: cytoplasmic YBX1c and nuclear YBX1n. Arrows
indicating nuclear YBX1n and cytoplasmatic YBX1c stainings (a) and enhancement after RAS induction (b,d). Scale bar: 100 μm.
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D38B1,#4267; dilution 1:100; Cell Signaling Technology, Cambridge, UK),
HER2/ERRB2 (rabbit polyclonal HER2/ERBB2 #2242; dilution 1:50; Cell
Signaling Technology), HER3/ERBB3 (rabbit polyclonal ERBB3 Antibody
LS-C90418; dilution 1:100; LifeSpan Biosciences, Inc., Seattle, WA, USA),
c-terminal HER4 (rabbit polyclonal ERBB4 LS-C97506; dilution 1:100;
LifeSpan Biosciences, Inc.) and n-terminal HER4/ERRB4 (polyclonal rabbit
ERBB4 N-term, #AP7631a; dilution 1:50; Abgent, San Diego, CA, USA) and
RFP (anti-RFP, #600-401-379; dilution 1:200, Rockland, Gilbertsville, PA,
USA) were applied according to the manufacturer’s guide. For the staining
procedure, we used the Dako REAL-kit (Dako Denmark A/S, Glostrup,
Denmark). Anti-RFP was processed with ImmPRESS secondary antibody
and NovaRED substrate kits (Vector Labs, Burlingame, CA, USA). IHC Slides
were washed in TBS and the secondary antibody was applied. The slides
were washed again in TBS and the HRP-link was applied. At last, the
Figure 4. (a) Expression of RAS, pERK and YBX1c in Caco2 cells following KRAS induction for 30 min, 4 , 24 and 48 h. RAS and phospho-ERK1/2
are induced after 24 and 48 h following doxycycline treatment. Phospho-ERK increases strongly after 30 min and 4 h following TGFα
application; EGFR is induced 48 h after U0126 treatment. W/O (1), DMSO (2), U0126 (3), aqua bidest (4), doxycycline (5), TGFα (6). (b) RAS is
upregulated after 24 h and 48 h of doxycycline treatment; again no change of YBX1n. W/O (1), DMSO (2), U0126 (3), aqua bidest (4),
doxycycline (5), TGFα (6).
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chromogen substrate diluted in buffer solution was incubated on the slides
and a proper staining degree was determined with light microscopy.
Staining reaction was stopped within a water bath. Hematoxylin core
staining solution was applied, followed by alcohol ﬁxation and cover-slip.
For negative controls the primary antibody was omitted (Supplementary
Figure S1). Pictures were taken with an Olympus BX53 light microscope
linked to a DP25 camera (Olympus Corporation, Tokyo, Japan).
Cell culture and immunoﬂuorescence
We used a previously modiﬁed Caco2 cell line stably transfected with a
doxycycline-inducible KRASG12V,48 which allows for conditional KRAS
expression. Cells were grown at 37 °C, 5% CO2 in Dulbecco’s
Modiﬁed Eagle’s Medium (DMEM; Life Technologies, Thermo Fisher
Scientiﬁc, Carlsbad, CA, USA) supplemented with 10% v/v FBS, Penicillin
G (100U/ml) and Streptomycin (100 μg/ml; D10 medium) with Puromycin
(5 μl/ml) and Blasticidin (5 μg/ml). Cells were plated at 1x104 cells
per chamber (24-h measurement) or 1.25 × 103 cells per chamber
(96-h measurement) in an eight-well chamber slide system (Lab-Tek II
Chamber Slide, Thermo Fisher Scientiﬁc, Inc., Rochester, NY, USA).
For protein extraction and western blotting, 2.5 × 104 cells per well
(24-h measurement) or 1.25x104 cells per well (96-h measurement) were
plated in 60 mm dishes. KRASG12V was induced with Doxycyclin at 2 μg/ml.
DMSO was added as a control at 10 μM. The MEK inhibitor U0126
was added at 10 μM; TGFα was added at 20 ng/ml (30 min and 4 h) and
10 ng/ml (24 and 48 h). Prior to immunoﬂuorescence, cells were ﬁxed with
4% of formaldehyde at room temperature. Fixative was removed, cells
were washed with 1x PBS and blocking solution containing 5% BSA was
applied. Blocking solution was aspirated and YBX1c and YBX1n were
applied in a 1:100 dilution and incubated overnight at 4 °C. The primary
antibody was removed, the cells were washed with TBS three times and
the secondary antibody (Red Fluorescent AlexaFluor 546 goat anti-rabbit
IgG, Life Technologies, Thermo Fisher Scientiﬁc) was applied. After TBS
rinsing the washing solution was removed. The chamber grid was carefully
detached. The silicone gasket was removed with a thin-bladed spatula, the
slides were coverslipped using a 2 μg/ml 1,4-Diazabicyclo[2.2.2]octane-
based solution (460 mg, 18 mg Glycerin and 2 ml 0.2 M Tris solution at pH
8.0) and stored in a dark environment at 4 °C. Pictures of Immunoﬂuor-
escence stains were taken using a Zeiss Axiovert 40 CFL microscope linked
to an AxioCam MRc camera (Carl Zeiss AG, Oberkochen, Germany).
Immunohistochemical evaluation
Immunohistochemical staining was evaluated independently by two
pathologists (HB and FR). An immunoreactive score (IRS)49 was applied,
which was calculated as a product of staining intensity and the percentage
of stained tumor cells (0 = no staining visible, 1 =weak staining,
2 =moderate staining, 3 = strong staining) and percentage of positive
cells (0 = no cells, 1⩽ 10% positive, 2 = 10–50% positive, 3 = 50–80%
positive, 4⩾ 80% positive). Tumor samples with a result between 0 and
Figure 5. Immunohistochemical staining using YBX1n and YBX1c antibodies in mouse xenografts of Caco2 cells prior to (− ) or following KRAS
oncogene induction (+). Three independent tumors, C2, C3 and C6 were stained. Scale bar: 100 μm.
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6 (group1) or between 8 and 12 (group2) were assigned to subgroups with
low-expression pattern1 and high-expression pattern.2
Western blot
About 40 μg of whole cell lysates per lane were separated by SDS–PAGE at
100mA for 60 min. LI-COR blocking buffer (LI-COR Biosciences, Lincoln, NE,
USA) and PBS solution was applied 1:1 for 60 min. We used Pan-RAS
primary antibody (mouse monoclonal Anti-Pan-Ras, MABS195; dilution
1:500; Merck Millipore, Merck KGaA, Darmstadt, Germany) for detection of
total RAS protein. YBX1c and YBX1n antibodies were applied at 1:1500.
GAPDH served as a control (mouse monoclonal GAPDH, clone 6C5,
AM4300; dilution 1:15000; Life Technologies, Thermo Fisher Scientiﬁc). EGF
receptor (rabbit monoclonal EGF Receptor D38B1, #4267; dilution 1:1000)
and phospho-MEK1/2 (rabbit polyclonal Phospho-MEK1/2 (Ser217/221),
#9121; dilution 1:1000; Cell Signaling Technology) were used for western
blot analysis. β-Tubulin (rabbit polyclonal β-Tubulin, #2146; dilution 1:1000;
Cell Signaling Technology) served as a loading control in the latter western
blot analyses. Anti-rabbit and anti-mouse antibodies coupled to
Fluorescent AlexaFluor Dyes (Green Fluorescent Red Fluorescent
AlexaFluor 488 goat anti-mouse IgG and Red Fluorescent AlexaFluor 546
goat anti-rabbit IgG, dilution 1:10000) were applied as secondary
antibodies and detected with an infrared imaging system (Odyssey,
LI-COR Biosciences, Lincoln, NE, USA). For semi-quantitative evaluation,
YBX1 and EGFR values were normalized against GADPH and β-Tubulin
levels.
Mouse intestine samples and Caco2 cell-derived xenografts
Transgenic mice harboring oncogenes in the Gt(ROSA)26Sor locus
were described previously.50,51 For short-term KRASV12 induction
in vivo, mice were provided doxycycline at 4 mg/ml in a 1% sucrose
solution via the drinking water for 3–4 days. Induced and control mice
were killed, and intestines (Jejunum/Ileum) were ﬁxed for 12–24 h in a
4% formalin solution, before they were dehydrated and embedded in
parafﬁn. For immunohistochemistry, 4 μm sections were used, as
described above. Experiments were approved by Berlin authorities
LAGeSo (G0185/09).
For xenografts, 3x106 Caco2 cells stably transfected with a doxycycline-
inducible KRASG12V48 and suspended in a 1:1 mixture of matrigel and PBS
were injected s.c. into NMRI nu/nu and NSG mice (6 mice per group). For
transgene induction, 2 mg/ml doxycycline (in 5% sucrose) was adminis-
tered ad libitum starting at day 1 after injection. Mice were observed for
35 days and maintained under sterile and controlled conditions (22 °C, ca.
50% relative humidity, 12 h light–dark cycle, autoclaved food and bedding,
acidiﬁed drinking water). Tumor diameters were determined 2× weekly by
caliper measurements and tumor volume was determined with the
formula TV= (width2 x length x 0.5); body weight was measured as a
parameter for tolerability. Xenograft experiments were approved by Berlin
authorities LAGeSo (A0452/08).
Statistical analysis
Data sets were administrated with Microsoft Access 2003, statistical
analysis was performed using the SPSS 21.0 software (SPSS, Chicago, IL,
USA). Survival analyses were calculated with Kaplan–Meier functions
and Log-rank test. Linear regression model and χ2-test were used to
describe the correlation between expression data and clinicopathological
data. A non-parametric correlation test (Spearman-Rho) was applied
to describe the correlations between expression data. All tests
were two-sided and P-values o0.05 were considered statistically
signiﬁcant.
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